172 related articles for article (PubMed ID: 38188684)
1. Aldo-keto reductase family member C3 (AKR1C3) promotes hepatocellular carcinoma cell growth by producing prostaglandin F2α.
Jeng KS; Cheng PY; Lin YH; Liu PC; Tseng PH; Wang YC; Chang CF; Leu CM
Oncol Res; 2023; 32(1):163-174. PubMed ID: 38188684
[TBL] [Abstract][Full Text] [Related]
2. Diagnostic and prognostic values of AKR1C3 and AKR1D1 in hepatocellular carcinoma.
Zhu P; Feng R; Lu X; Liao Y; Du Z; Zhai W; Chen K
Aging (Albany NY); 2021 Jan; 13(3):4138-4156. PubMed ID: 33493134
[TBL] [Abstract][Full Text] [Related]
3. AKR1C3-dependent lipid droplet formation confers hepatocellular carcinoma cell adaptability to targeted therapy.
Wu C; Dai C; Li X; Sun M; Chu H; Xuan Q; Yin Y; Fang C; Yang F; Jiang Z; Lv Q; He K; Qu Y; Zhao B; Cai K; Zhang S; Sun R; Xu G; Zhang L; Sun S; Liu Y
Theranostics; 2022; 12(18):7681-7698. PubMed ID: 36451864
[No Abstract] [Full Text] [Related]
4. Overexpression of AKR1C3 significantly enhances human prostate cancer cells resistance to radiation.
Sun SQ; Gu X; Gao XS; Li Y; Yu H; Xiong W; Yu H; Wang W; Li Y; Teng Y; Zhou D
Oncotarget; 2016 Jul; 7(30):48050-48058. PubMed ID: 27385003
[TBL] [Abstract][Full Text] [Related]
5. AKR1C3 regulated by NRF2/MAFG complex promotes proliferation via stabilizing PARP1 in hepatocellular carcinoma.
Pan D; Yang W; Zeng Y; Qin H; Xu Y; Gui Y; Fan X; Tian G; Wu Y; Sun H; Ye Y; Yang S; Zhou J; Guo Q; Zhao L
Oncogene; 2022 Jul; 41(31):3846-3858. PubMed ID: 35773412
[TBL] [Abstract][Full Text] [Related]
6. AKR1C3 suppresses ferroptosis in hepatocellular carcinoma through regulation of YAP/SLC7A11 signaling pathway.
Chen J; Zhang J; Tian W; Ge C; Su Y; Li J; Tian H
Mol Carcinog; 2023 Jun; 62(6):833-844. PubMed ID: 36920042
[TBL] [Abstract][Full Text] [Related]
7. A Positive Feedback Loop of AKR1C3-Mediated Activation of NF-κB and STAT3 Facilitates Proliferation and Metastasis in Hepatocellular Carcinoma.
Zhou Q; Tian W; Jiang Z; Huang T; Ge C; Liu T; Zhao F; Chen T; Cui Y; Li H; Yao M; Li J; Tian H
Cancer Res; 2021 Mar; 81(5):1361-1374. PubMed ID: 33361392
[TBL] [Abstract][Full Text] [Related]
8. Pre-clinical activity of PR-104 as monotherapy and in combination with sorafenib in hepatocellular carcinoma.
Abbattista MR; Jamieson SM; Gu Y; Nickel JE; Pullen SM; Patterson AV; Wilson WR; Guise CP
Cancer Biol Ther; 2015; 16(4):610-22. PubMed ID: 25869917
[TBL] [Abstract][Full Text] [Related]
9. Aldo-keto reductase 1C3 expression in MCF-7 cells reveals roles in steroid hormone and prostaglandin metabolism that may explain its over-expression in breast cancer.
Byrns MC; Duan L; Lee SH; Blair IA; Penning TM
J Steroid Biochem Mol Biol; 2010 Feb; 118(3):177-87. PubMed ID: 20036328
[TBL] [Abstract][Full Text] [Related]
10. Knockdown of AKR1C3 Promoted Sorafenib Sensitivity Through Inhibiting the Phosphorylation of AKT in Hepatocellular Carcinoma.
Zheng J; Yang Z; Li Y; Yang L; Yao R
Front Oncol; 2022; 12():823491. PubMed ID: 35359392
[TBL] [Abstract][Full Text] [Related]
11. Aldo-keto reductase 1C3 is overexpressed in skin squamous cell carcinoma (SCC) and affects SCC growth via prostaglandin metabolism.
Mantel A; Carpenter-Mendini A; VanBuskirk J; Pentland AP
Exp Dermatol; 2014 Aug; 23(8):573-8. PubMed ID: 24917395
[TBL] [Abstract][Full Text] [Related]
12. An indomethacin analogue, N-(4-chlorobenzoyl)-melatonin, is a selective inhibitor of aldo-keto reductase 1C3 (type 2 3alpha-HSD, type 5 17beta-HSD, and prostaglandin F synthase), a potential target for the treatment of hormone dependent and hormone independent malignancies.
Byrns MC; Steckelbroeck S; Penning TM
Biochem Pharmacol; 2008 Jan; 75(2):484-93. PubMed ID: 17950253
[TBL] [Abstract][Full Text] [Related]
13. Aldo-keto reductase family 1 member C3 (AKR1C3) is a biomarker and therapeutic target for castration-resistant prostate cancer.
Hamid AR; Pfeiffer MJ; Verhaegh GW; Schaafsma E; Brandt A; Sweep FC; Sedelaar JP; Schalken JA
Mol Med; 2013 Jan; 18(1):1449-55. PubMed ID: 23196782
[TBL] [Abstract][Full Text] [Related]
14. Expression of aldo-keto reductase family 1 member C3 (AKR1C3) in neuroendocrine tumors & adenocarcinomas of pancreas, gastrointestinal tract, and lung.
Chang TS; Lin HK; Rogers KA; Brame LS; Yeh MM; Yang Q; Fung KM
Int J Clin Exp Pathol; 2013; 6(11):2419-29. PubMed ID: 24228104
[TBL] [Abstract][Full Text] [Related]
15. Overexpression of aldo-keto reductase 1C3 (AKR1C3) in LNCaP cells diverts androgen metabolism towards testosterone resulting in resistance to the 5α-reductase inhibitor finasteride.
Byrns MC; Mindnich R; Duan L; Penning TM
J Steroid Biochem Mol Biol; 2012 May; 130(1-2):7-15. PubMed ID: 22265960
[TBL] [Abstract][Full Text] [Related]
16. Expression of AKR1B1, AKR1C3 and other genes of prostaglandin F2α biosynthesis and action in ovarian endometriosis tissue and in model cell lines.
Sinreih M; Anko M; Kene NH; Kocbek V; Rižner TL
Chem Biol Interact; 2015 Jun; 234():320-31. PubMed ID: 25446850
[TBL] [Abstract][Full Text] [Related]
17. Type 5 17beta-hydroxysteroid dehydrogenase/prostaglandin F synthase (AKR1C3): role in breast cancer and inhibition by non-steroidal anti-inflammatory drug analogs.
Byrns MC; Penning TM
Chem Biol Interact; 2009 Mar; 178(1-3):221-7. PubMed ID: 19010312
[TBL] [Abstract][Full Text] [Related]
18. 11β-Prostaglandin F2α, a bioactive metabolite catalyzed by AKR1C3, stimulates prostaglandin F receptor and induces slug expression in breast cancer.
Yoda T; Kikuchi K; Miki Y; Onodera Y; Hata S; Takagi K; Nakamura Y; Hirakawa H; Ishida T; Suzuki T; Ohuchi N; Sasano H; McNamara KM
Mol Cell Endocrinol; 2015 Sep; 413():236-47. PubMed ID: 26170067
[TBL] [Abstract][Full Text] [Related]
19. Crystal structures of three classes of non-steroidal anti-inflammatory drugs in complex with aldo-keto reductase 1C3.
Flanagan JU; Yosaatmadja Y; Teague RM; Chai MZ; Turnbull AP; Squire CJ
PLoS One; 2012; 7(8):e43965. PubMed ID: 22937138
[TBL] [Abstract][Full Text] [Related]
20. Buparlisib is a novel inhibitor of daunorubicin reduction mediated by aldo-keto reductase 1C3.
Bukum N; Novotna E; Morell A; Hofman J; Wsol V
Chem Biol Interact; 2019 Apr; 302():101-107. PubMed ID: 30703376
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
